| Document Date: 2014-04-23 10:17:58
Open Document File Size: 127,03 KBShare Result on Facebook
City Cincinnati / Shanghai / San Francisco / Herzliya / Mumbai / New York / / Company Satter Investment Management / Novartis Venture Funds / Venture Investors / OrbiMed / Athenian Venture Partners / Triathlon Medical Ventures / Aerpio Therapeutics Inc. / Kearny Venture Partners / / Currency USD / / / Event Employment Change / FDA Phase / Funding / / IndustryTerm biopharmaceutical / treatment of DME and other retinal diseases / clinical‐stage biopharmaceutical / healthcare / healthcare sector / therapies for vascular diseases / venture capital start-ups / / MedicalCondition vascular diseases / inflammatory bowel disease / disease / retinal diseases / Crohn's disease / ulcerative colitis / diabetic macular edema / / MedicalTreatment innovative therapies / / Person Q. Khuong / Joseph Gardner / Heather Behler / / / Position President and CEO / Office Manager / leader in the development / board member / / Product AKB-4924 / AKB-9778 / / ProvinceOrState Ohio / / URL www.aerpio.com / /
SocialTag |
FOR IMMEDIATE RELEASE Aerpio Therapeutics Closes $22M Financing --Proceeds Support Expanded Development Program for AKB-9778 and Advancement of HIF1 Activator into the Clinic-Cincinnati, OH, April 23, 2014 – Aerpio The